openPR Logo
Press release

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics- Pipeline Analysis 2018 | GTx, Inc., Immunomedics, Clovis Oncology

05-07-2019 12:22 PM CET | Health & Medicine

Press release from: Hormone Refractory-Pharma Proff

Hormone Refractory (Castration Resistant,

Prostate cancer occurs when cells in prostate glands grow uncontrollably. Prostate is an exocrine gland that makes the fluid part of semen and lie below the bladder in front of the rectum. As per the National Institute of Health (NIH), 10.7% of all new cases of cancer in the U.S. are of prostate cancer.

Download the sample report @

Moreover, according to the National Cancer Institute, prostate cancer is the second leading cause of cancer deaths in men. The symptoms of the disease include frequent urination, difficulty in holding urine, painful or burning sensation while urinating, blood in the urine, blood in semen, erectile dysfunction, and pain in the lower back or pelvis or thighs. The treatment options for prostate cancer include hormone therapy, chemotherapy and vaccine treatment.

Get the detailed analysis @

The drug candidates of hormone refractory (castration resistant, androgen-independent) prostate cancer pipeline include, but not limited to, AT-001 and Rucaparib. Some of the companies having drugs in the hormone refractory (castration resistant, androgen-independent) prostate cancer pipeline includes GTx Inc., Immunomedics Inc., and Clovis Oncology Inc.

Make enquiry before purchase @

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics- Pipeline Analysis 2018 | GTx, Inc., Immunomedics, Clovis Oncology here

News-ID: 1729686 • Views: 443

More Releases for Prostate

Global Prostate Cancer Therapeutics Market
Global Prostate Cancer Therapeutics Market – Industry Analysis and Forecast (2018-2026) –By Product Type, End User, and Region. Global Prostate Cancer Therapeutics Market was valued at US$ 9.21 Bn in 2017 and is expected to reach US$ 16.21 Bn by 2026, at a CAGR of 7.33 % during a forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data,
Prostate Cancer Drugs Market Research Report 2018
This report studies the global Prostate Cancer Drugs market status and forecast, categorizes the global Prostate Cancer Drugs market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). Download FREE Sample of this Report @ The major manufacturers covered in this report AbbVie Astellas Pharma Astra Zeneca Johnson & Johnson Sanofi GlaxoSmithKline Merck Group Novartis Amgen Bayer HealthCare Ferring Pharmaceutical Janssen Pharmaceuticals Endo Pharmaceuticals BMS Takeda
Prostate Biopsy Forceps Market
Global Prostate Biopsy Forceps Market Status and Trend Report offers a comprehensive analysis on Prostate Biopsy Forceps industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Browse Full Report with TOC: Key questions answered by this report include: Worldwide and Regional Market Size of Prostate Biopsy Forceps 2013-2017,
Prostate Cancer - Pipeline Review, H1 2017
Report Hive Market Research Released a New Research Report of 1845 pages on Title " Prostate Cancer - Pipeline Review, H1 2017 "with detailed Analysis, Forecast and Strategies. Prostate Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides an overview of the Prostate Cancer (Oncology) pipeline landscape. Prostate cancer is a form of cancer that affects men and
US Prostate Cancer Drug Pipeline Analysis
Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US. According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from 206,640 men diagnosed with the condition during 2009. The number of men being actively treated for prostrate disorders such as benign
Global Prostate Biopsy Market 2017-2021
Biopsy is a clinical procedure primarily used in the detection and extraction of malignant or cancerous cells and their abnormal growth in the body for further analysis and interpretation of diseases. The purpose of removing tissues or cells during the procedure is mainly to limit the spread of tumor, minimize morbidity, and eliminate interference with future treatments. Technavios analysts forecast the global prostate biopsy market to grow at a CAGR of